Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 11/20 | 0.52 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16691325 | 0.88 | CKS1B (0.52) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL23173694 | 0.87 | CKS1B (0.51) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL22102278 | 0.86 | CKS1B (0.53) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL16691339 | 0.86 | SUV39H2 (0.51) | SUV39H2CKS1BSKP1SKP2CFTR | |
| SCHEMBL5226281 | 0.85 | CFTR (0.49) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL2271310 | 0.85 | CKS1B (0.49) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL1456142 | 0.84 | CKS1B (0.54) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL21434104 | 0.84 | SMO (0.49) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL27655935 | 0.83 | SUV39H2 (0.54) | SUV39H2CKS1BSKP1SKP2CNR1 | |
| SCHEMBL2270934 | 0.83 | PSEN1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015138689-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015066696-A1 | FUSED MORPHLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | SUV39H2 250/4885CKS1B 3966/4885SKP1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.